Public Employees Retirement Association of Colorado Sells 784 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Public Employees Retirement Association of Colorado lessened its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 13.0% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 5,265 shares of the company’s stock after selling 784 shares during the period. Public Employees Retirement Association of Colorado’s holdings in Amphastar Pharmaceuticals were worth $211,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Bridge City Capital LLC lifted its position in shares of Amphastar Pharmaceuticals by 0.8% during the 1st quarter. Bridge City Capital LLC now owns 34,773 shares of the company’s stock valued at $1,527,000 after buying an additional 275 shares in the last quarter. Crossmark Global Holdings Inc. boosted its position in shares of Amphastar Pharmaceuticals by 2.5% in the second quarter. Crossmark Global Holdings Inc. now owns 11,300 shares of the company’s stock worth $452,000 after purchasing an additional 275 shares during the period. Blue Trust Inc. increased its stake in shares of Amphastar Pharmaceuticals by 23.9% in the second quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock worth $70,000 after purchasing an additional 309 shares in the last quarter. Arizona State Retirement System raised its position in shares of Amphastar Pharmaceuticals by 3.9% during the 2nd quarter. Arizona State Retirement System now owns 10,943 shares of the company’s stock valued at $438,000 after purchasing an additional 410 shares during the period. Finally, Texas Permanent School Fund Corp raised its position in shares of Amphastar Pharmaceuticals by 1.3% during the 1st quarter. Texas Permanent School Fund Corp now owns 32,704 shares of the company’s stock valued at $1,436,000 after purchasing an additional 424 shares during the period. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Price Performance

Shares of AMPH opened at $48.02 on Monday. The company has a market cap of $2.35 billion, a price-to-earnings ratio of 16.62, a price-to-earnings-growth ratio of 0.92 and a beta of 0.82. Amphastar Pharmaceuticals, Inc. has a twelve month low of $36.56 and a twelve month high of $65.92. The company has a quick ratio of 2.63, a current ratio of 3.52 and a debt-to-equity ratio of 0.82. The company has a 50 day moving average of $45.39 and a two-hundred day moving average of $42.72.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings data on Wednesday, August 7th. The company reported $0.85 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.75 by $0.10. Amphastar Pharmaceuticals had a return on equity of 29.79% and a net margin of 23.36%. The firm had revenue of $182.39 million during the quarter, compared to analysts’ expectations of $171.29 million. As a group, analysts predict that Amphastar Pharmaceuticals, Inc. will post 3.71 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. StockNews.com raised Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, September 20th. Piper Sandler reduced their price objective on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating on the stock in a research report on Thursday, August 8th. Finally, Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, August 8th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $63.00.

Insider Activity at Amphastar Pharmaceuticals

In related news, EVP Rong Zhou sold 4,000 shares of Amphastar Pharmaceuticals stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $48.35, for a total value of $193,400.00. Following the sale, the executive vice president now directly owns 118,388 shares in the company, valued at approximately $5,724,059.80. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, EVP Rong Zhou sold 4,000 shares of Amphastar Pharmaceuticals stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $48.35, for a total value of $193,400.00. Following the sale, the executive vice president now directly owns 118,388 shares in the company, valued at approximately $5,724,059.80. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Floyd F. Petersen sold 3,000 shares of Amphastar Pharmaceuticals stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $46.47, for a total value of $139,410.00. Following the completion of the sale, the director now owns 75,409 shares in the company, valued at $3,504,256.23. The disclosure for this sale can be found here. Insiders sold a total of 34,383 shares of company stock worth $1,524,123 in the last three months. Company insiders own 27.10% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.